Clinical Trials Directory

Trials / Completed

CompletedNCT01804452

4 Repeat Tauopathy Neuroimaging Initiative

Observational Longitudinal Study of Magnetic Resonance Imaging, Specimen Biomarkers, and Clinical Progression in Progressive Supranuclear Palsy and Corticobasal Degeneration

Status
Completed
Phase
Study type
Observational
Enrollment
110 (estimated)
Sponsor
University of California, San Francisco · Academic / Other
Sex
All
Age
45 Years – 90 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate several different tests, including brain imaging, eye movement testing, body fluid samples, measurements of memory and other thinking abilities, and measures of functional independence in the hope that this information can be used to guide diagnosis and treatment of PSP and CBD in the future. Recent advances in our understanding of the biological causes of these diseases offer hope for new treatments. As such treatments are developed, sensitive and specific biological measurements (biomarkers) will be needed to provide precise and direct measures of the state of the brain, which will improve the statistical power of clinical trials. Brain imaging with Magnetic Resonance Imaging (MRI) has previously been used to measure disease-related changes in the brain. The goal of this study is to identify the best methods of analysis (including eye movements, imaging, and behavioral measures) for tracking PSP and CBD over time. In addition, certain biomarkers in the blood and cerebrospinal fluid might also be useful for following these diseases over time. This study will examine the value of blood and CSF biomarkers relative to brain imaging and functional measures.

Conditions

Interventions

TypeNameDescription
OTHERObservational Study

Timeline

Start date
2011-01-10
Primary completion
2016-02-28
Completion
2016-03-01
First posted
2013-03-05
Last updated
2025-05-08

Locations

2 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT01804452. Inclusion in this directory is not an endorsement.